Skip to main content

Advertisement

SpringerLink
Log in

Clinical applications of receptor-binding radiopharmaceutical 99mTc-Tilmanocept: sentinel node biopsy and beyond

  • Mini-Review
  • Published:
Clinical and Translational Imaging Aims and scope Submit manuscript

Abstract

Purpose

99mTc-tilmanocept is the first mannose-containing, receptor-directed, radiopharmaceutical for molecular imaging and mapping of sentinel lymph nodes (SLNs) in solid tumor staging. This review focuses on the approved and innovative clinical application of 99mTc-tilmanocept.

Results and conclusion

99mTc-Tilmanocept is a new-generation radiotracer designed to overcome certain limitations of the conventionally used radiocolloids. The superior efficacy profile of 99mTc-tilmanocept has been demonstrated in several preclinical and clinical studies based on its specific properties like rapid injection site clearance, high uptake in the first node, and low distal node accumulation. The capability of 99mTc-tilmanocept for selective molecular imaging of the CD206 receptor may be used for diagnosis and treatment of several macrophage mediated diseases, including autoimmune diseases, infectious diseases (HIV and tuberculosis), neurodegenerative disorders (dementias) and cardiovascular disease (vulnerable plaque and atherosclerosis).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Vera DR, Wallace AM, Hoh CK et al (2001) A synthetic macromoleculefor sentinel node detection: 99mTc-DTPA-mannosyl-dextran. J Nucl Med 42(951–9):28

    Google Scholar 

  2. Wallace AM, Hoh CK, Vera DR et al (2003) Lymphoseek: a molecular radiopharmceutical for sentinel node detection. Ann Surg Oncol 10(531–8):29

    Google Scholar 

  3. Torrelles JB, Azad AK, Henning LC et al (2008) Role of C-type lectins in mycobacterial infections. Curr Drug Targets 9:102–112

    Article  CAS  Google Scholar 

  4. Stahl P, Schlesinger PH, Sigardson E et al (1980) Receptor-mediated pinocytosis of mannose glycoconjugates by macrophages: characterization and evidence for receptor recycling. Cell 19(1):207

    Article  CAS  Google Scholar 

  5. Irache JM, Salman HH, Gamazo C et al (2008) Mannose-targeted systems for the delivery of therapeutics. Expert Opin Drug Deliv 5(6):703–724

    Article  CAS  Google Scholar 

  6. Cabanas RM (1977) An approach for the treatment of penile carcinoma. Cancer 39(456–66):24

    Google Scholar 

  7. Morton DL, Wen DR, Wong JH et al (1992) Technicaldetails of intraoperative lymphatic mapping for early stage melanoma. ArchSurg 127(392–9):3

    Google Scholar 

  8. Méndez J, Wallace AM, Hoh CK et al (2003) Detection of gastric and colonic sentinel nodes through endoscopic administration of 99mTc-DTPA-mannosyl-dextran in pigs. J Nucl Med 44(10):1677–1681

    PubMed  Google Scholar 

  9. Ellner SJ, Hoh CK, Vera DR et al (2003) Dose-dependent biodistribution of 99mTc DTPA-mannosyl-dextran for breast cancer sentinel lymph node mapping. Nucl Med Biol 30(8):805–810

    Article  CAS  Google Scholar 

  10. Giuliano AE, Kirgan DM, Guenther JM et al (1994) Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 220:391–398

    Article  CAS  Google Scholar 

  11. Veronesi U, Paganelli G, Galimberti V et al (1997) Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. Lancet 349:1864–1867

    Article  CAS  Google Scholar 

  12. Krag D, Weaver D, Ashikaga T et al (1998) The sentinel node in breast cancer – a multicenter validation study. N Engl J Med 339(14):941–946

    Article  CAS  Google Scholar 

  13. McMasters KM, Tuttle TM, Carlson DJ et al (2000) Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 18(13):2560–2566

    Article  CAS  Google Scholar 

  14. Wallace AM, Han LK, Povoski SP et al (2013) Comparative evaluation of 99mTcTilmanocept for sentinel lymph node map-ping in breast cancer patients: results of two phase 3 trials. Ann Surg Oncol 20(2590–9):33

    Google Scholar 

  15. Baker JL, Pu M, Tokin CA, Hoh CK, Vera DR, Messer K et al (2015) Comparison of 99mTc-tilmanocept and filtered 99mTc sulfur colloid for identification of SLNs in breastcancer patients. Ann Surg Oncol 22(40–5):4

    Google Scholar 

  16. Tokin CA, Cope FO, Metz WL et al (2012) The efficacy of Tilmanocept in sentinel lymph mode mapping and identification in breast cancer patients: a comparative review and meta-analysis of the 99mTc-labeled nanocolloid human serum albumin standard of care. Clin Exp Metastasis 29(7):681–686

    Article  CAS  Google Scholar 

  17. Unkart JT, Proudfoot J, Wallace AM (2018) Outcomes of “one-day” vs “two-day” injec-tion protocols using Tc-99m tilmanocept for sentinel lymph node biopsy inbreast cancer. Breast J 24(526–30):48

    Google Scholar 

  18. Morton DL, Thompson JF, Cochran AJ et al (2014) Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 370(7):599–609

    Article  CAS  Google Scholar 

  19. Sondak VK, King DW, Zager JS et al (2013) Combined analysis of phase III trials evaluating 99mTc tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol 20(2):680–688

    Article  Google Scholar 

  20. Leong SP, Kim J, Ross MI et al (2011) A phase 2 study of 99mTc-tilmanocept in the detection of sentinel lymph nodes in melanoma and breast cancer. Ann Surg Oncol 18:961–969

    Article  Google Scholar 

  21. Liu M, Wang SJ, Yang X et al (2017) Diagnostic efficacy of sentinel lymph node biopsyin early oral squamous cell carcinoma: a meta-analysis of 66 studies. PLoS ONE 12:00170322

    Google Scholar 

  22. Civantos FJ, Zitsch RP, Schuller DE et al (2010) Sentinellymph node biopsy accurately stages the regional lymph nodes for T1–T2 oralsquamous cell carcinomas: results of a prospective multi-institutional trial. J Clin Oncol 28(1395–400):53

    Google Scholar 

  23. Marcinow AM, Hall N, Byrum E et al (2013) Use of a novelreceptor-targeted (CD206) radiotracer, 99mTc-tilmanocept, and SPECT/CT forsentinel lymph node detection in oral cavity squamous cell carcinoma: initial institutional report in an ongoing phase 3 study. JAMA Otolaryngol Head NeckSurg 139:895–902

    Article  Google Scholar 

  24. Agrawal A, Civantos FJ, Brumund KT et al (2015) 99mTcTilmanocept accurately detects sentinel lymph nodes and predicts node pathology status in patients with oral squamous cell carcinoma of the head and neck: results of a phase III multi-institutional trial. Ann Surg Oncol 22:3708–3715

    Article  Google Scholar 

  25. den Toom IJ, Mahieu R, van Rooij R et al (2020) Sentinel lymph node detection in oral cancer: a within-patient comparison between 99mTc-tilmanocept and 99mTc-nanocolloid. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-020-04984-8

    Article  Google Scholar 

  26. Trials CU. U.S National Institutes of Health. Available at: https://clinicaltrials.gov/ct2/ show/NCT03157167

  27. Cope FO, Abbruzzese B, Sanders J et al (2016) The inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach. Nucl Med Biol 43(3):215–2525

    Article  CAS  Google Scholar 

  28. Varasteh Z, Hyafil F, Anizan N et al (2017) Targeting mannose receptor expression on macrophages in atherosclerotic plaques of apolipoprotein E-knockout mice using 111In-tilmanocept. EJNMMI Res 7(1):40

    Article  Google Scholar 

  29. Zanni MV, Toribio M, Wilks MQ et al (2017) Application of a Novel CD206+ Macrophage-Specific Arterial Imaging Strategy in HIV-Infected Individuals. J Infect Dis 215(8):1264–1269

    Article  CAS  Google Scholar 

  30. Trials CU. U.S National Institutes of Health. Available at: https://clinicaltrials.gov/ct2/ show/ NCT02865434

  31. Qin Z, Hoh CK, Olson ES et al (2019) Molecular Imaging of the Glomerulus via Mesangial Cell Uptake of Radiolabeled Tilmanocept. J Nucl Med. https://doi.org/10.2967/jnumed.118.223727

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

    Alice Lorenzoni & Marco Maccauro

  2. Melanoma and Sarcoma, Department of Surgery, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

    Mario Santinami

Authors
  1. Alice Lorenzoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mario Santinami
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marco Maccauro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alice Lorenzoni.

Ethics declarations

Conflict of interest

Alice Lorenzoni, Mario Santinami and Marco Maccauro declare that they have no conflict of interest.

Human and animal rights disclosure

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lorenzoni, A., Santinami, M. & Maccauro, M. Clinical applications of receptor-binding radiopharmaceutical 99mTc-Tilmanocept: sentinel node biopsy and beyond. Clin Transl Imaging 8, 413–418 (2020). https://doi.org/10.1007/s40336-020-00399-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40336-020-00399-5

Keywords

Search

Navigation